


Novel Therapeutic Approaches Targeting Microglia Biology for Neuroinflammatory Disorders



Astellas Pharma are an international pharmaceutical company seeking novel research programs targeting microglia biology for neuroinflammatory and/or neuroimmunological disorders. **Astellas are interested in microglia biology with a focus on disease/pathophysiology-specific microglia.** This could include aspects of the following, as well as other microglia-specific disease traits:

- Lysosomal function
- Pyroptosis
- Autoimmune/inflammatory diseases

Target Diseases

Diseases of particular interest are neuroinflammatory disorders which have a strong/clear relevance to a specific target. Research focused on the following areas is of highest interest:

- Synucleinopathies, such as Parkinson's disease and Multiple System Atrophy
- Hearing loss
- Autoimmune/autoinflammatory diseases
- Pyroptosis-associated diseases
- Highly creative proposals focused on microglia biology in other diseases is also within scope
- Astellas are most interested in opportunities focused on small molecule or antibody therapeutic approaches, but are also open to other modalities, including cell therapy, and CAR-macrophage/microglia/Tregs for neuroinflammation

Developmental Stage

- Astellas are interested in opportunities from the target identification preclinical stage through to clinical phase 1
- Therapeutic targets where the mechanism of action is proven or well understood is of highest interest
- Preclinical proof of concept has ideally been evaluated in a clinically translatable study (e.g. *in vitro* patient-derived/human/mammalian cells/tissues assay, *in vivo* animal model study). Non-mammalian models are of less interest

Out of Scope

Opportunities focused on microglia in the context of the microbiome, well-known target approaches, steroids, natural products and drug repurposing are outside of Astellas' research interests for this campaign.

Incentives for Academics

Submissions will be reviewed on a case by case basis, with outcomes potentially including research collaborations, licencing of assets and expansion of expertise in project infancy.

Opportunities sought

-  Technologies
-  Research projects
-  Spinout companies
-  Academics and expertise
-  Centres of excellence

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **15th March 2021 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

